Drug Monograph
AVASTIN
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Your search for bevacizumab returned 143 results
Drug Monograph
ZIRABEV
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Drug Monograph
MVASI
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
News
Bevacizumab Ups Progression-Free Survival in Ovarian Cancer
For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
News
ASCO: Continuing Avastin With 2nd-Line Chemo Ups Survival
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
News
Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Drug News
Bevacizumab Safe, Stable for Multiple Dosing From Single Vial
No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week
News
Endophthalmitis Risk May Not Be Higher With Bevacizumab After All
Ophthalmic injections of bevacizumab exhibited no greater risk of endophthalmitis than injections of ranibizumab, according to a new study published in JAMA Ophthalmology.
News
Bevacizumab Offers Lasting Improvement in Macular Edema
At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).
News
No Survival Improvement From Bevacizumab for Patients with Newly Diagnosed Glioblastoma
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.
